Alnylam Insider Amy Schulman Buys 11,250 Shares, Betting on RNA‑i Growth Amid Stock’s Slump
Alnylam insider Amy Schulman’s recent 11,250‑share purchase signals confidence in RNA‑i growth and Vutrisiran’s clinical promise.
3 minutes to read
Alnylam Pharmaceuticals Inc
Alnylam HR Officer’s 1,200‑Share Sell‑to‑Cover Order: A Routine Tax Move, Not a Confidence Signal
Alnylam’s HR chief sells 1,200 shares to cover RSU taxes – routine move, not a red flag. Learn why insider trades may not signal a shift and what’s next for the biotech’s pipeline.
4 minutes to read
Alnylam Executives Execute Mass Sell‑to‑Cover Trades: Tax‑Cover Sales Inflate Daily Share Supply, Yet Long‑Term Outlook Remains Bullish
Alnylam insider sales reveal routine tax‑cover moves, not panic—short‑term dips possible but long‑term growth stays bullish amid new RNA‑interference deals.
6 minutes to read
Alnylam CFO Buys 4,769 Shares in Steady Move, Reinforcing Insider Confidence Amid Pipeline Upside.
Alnylam CFO’s recent share purchase shows insider confidence in the rare‑disease drugmaker’s pipeline, reinforcing long‑term investment potential.
8 minutes to read
Alnylam Executives Stack Shares Amid Surge in Social‑Media Buzz, Sending a Bullish Signal to Investors
Alnylam insider buying signals confidence: Pushkal’s fresh shares, CEO and CFO activity, and analyst upgrades hint at a high‑growth biotech rally—watch the next clinical milestone to gauge real upside.
10 minutes to read